How to Identify Transthyretin Cardiac Amyloidosis at an Early Stage
-
- Izumiya Yasuhiro
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Japan
-
- Hayashi Hiroya
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Japan
-
- Ishikawa Hirotoshi
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Japan
-
- Shibata Atsushi
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Japan
-
- Yoshiyama Minoru
- Department of Cardiovascular Medicine, Osaka City University Graduate School of Medicine, Japan
Search this article
Abstract
<p>Cardiac involvement of systemic amyloidosis is preferentially observed in patients with amyloid light chain amyloidosis or transthyretin amyloidosis (ATTR). Owing to the development of diagnostic modalities and changes in recognition by physicians, transthyretin cardiac amyloidosis (ATTR-CA) is now understood to be a more common cause of heart failure than previously thought. Recent progress in disease-modifying therapeutic interventions, such as transthyretin stabilizers, has resulted in ATTR-CA changing from an incurable disease to a curable disease. These interventions are particularly effective in patients with mild symptoms of heart failure, thus indicating that early detection and a precise diagnosis are important for improving the prognosis. In this review article, we summarize the recent reports of early screening of ATTR-CA and describe some important points regarding the making of a precise diagnosis, especially focusing on histological evaluations. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 60 (1), 1-7, 2021-01-01
The Japanese Society of Internal Medicine
